Cetuximab (Cet) clearance and survival in patients (pts) with metastatic colorectal cancer (mCRC)

被引：1
|
作者：
Jiang, Di Maria
Sim, Hao-Wen
Siu, Lillian L.
Shapiro, Jeremy David
Liu, Geoffrey
Price, Timothy Jay
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 04期
关键词：
D O I：
10.1200/JCO.2017.35.4_suppl.699
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
699
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Modified FOLFOXIRI plus cetuximab (cet) as induction treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Preliminary results of the phase II randomized Macbeth trial by GONO group.
    Cremolini, Chiara
    Loupakis, Fotios
    Salvatore, Lisa
    Lonardi, Sara
    Battaglin, Francesca
    Gamucci, Teresa
    Grande, Roberta
    Di Fabio, Francesca
    Liimpe, Fabiola Lorena Rojas
    Ferrari, Laura
    Casagrande, Mariaelena
    Lucchesi, Sara
    Tonini, Giuseppe
    Banzi, Maria
    Valsuani, Chiara
    Corsi, Domenico C.
    Fontanini, Gabriella
    Tomcikova, Daniela
    Boni, Luca
    Falcone, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [22] An international consortium study in chemorefractory metastatic colorectal cancer (mCRC) patients (pts) to assess the impact of FCGR polymorphisms on cetuximab efficacy.
    Geva, R.
    Jensen, B. V.
    Fountzilas, G.
    Yoshino, T.
    Paez, D.
    Montagut, C.
    Sougklakos, I.
    Cappuzzo, F.
    Cervantes-Ruiperez, A.
    Papamichael, D.
    Frattini, M.
    Vincenzi, B.
    Macarulla, T.
    Loupakis, F.
    Spindler, K. G.
    Qvortrup, C.
    Ciardiello, F.
    Tejpar, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [23] Cetuximab and capecitabine as first-line treatment for elderly patients (pts) with metastatic colorectal cancer (mCRC): Preliminary results of TTD trial
    Gravalos, C.
    Rivera, F.
    Massuti, B.
    Sastre, J.
    Marcuello, E.
    Valladares, M.
    Gil, S.
    Abad, A.
    Diaz-Rubio, E.
    Aranda, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [24] Results of a german noninterventional study (NIS) of cetuximab-based therapy in pretreated-patients (pts) with metastatic colorectal cancer (mCRC).
    Jehn, C.
    Stenzel, K.
    Boening, L.
    Kroening, H.
    Possinger, K.
    Lueftner, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [25] CIRCULATING AMPHIREGULIN (AR) PLASMA LEVELS AS SURROGATE PHARMACODYNAMIC MARKERS OF EGFR INHIBITION WITH CETUXIMAB IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS)
    Cremolini, C.
    Loupakis, F.
    Fioravanti, A.
    Lupi, C.
    Orlandi, P.
    Salvatore, L.
    Fontanini, G.
    Danesi, R.
    Bocci, G.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 68 - 68
  • [26] Phase Ib/II study of ibrutinib (ibr) in combination with cetuximab (cetux) in patients (pts) with previously treated metastatic colorectal cancer (mCRC)
    Oh, D-Y.
    Arkenau, T.
    Lee, K-W.
    Alsina, M.
    Marti, F. M.
    Chung, I. J.
    Saif, W.
    Wang, D.
    O'Dwyer, P.
    Chau, I.
    Lee, M-A.
    Chong, E.
    Hilger-Rolfe, J.
    Cole, G., Jr.
    Kim, S. Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S428 - S428
  • [27] Cetuximab plus irinotecan in patients (pts) with metastatic colorectal cancer (mCRC) failing prior oxaliplatin-based therapy: the EPIC trial
    Scheithauer, W.
    Sobrero, A.
    Lenz, H. J.
    Maurel, J.
    Lutz, M.
    Middleton, G.
    Saleh, M.
    Zubel, A.
    Williams, K.
    Burris, H. A., III
    EJC SUPPLEMENTS, 2007, 5 (04): : 235 - 236
  • [28] A phase II study of cetuximab (cet) and mFOLFOX6 in metastatic colorectal cancer (mCRC) (JACCRO CC-05)
    Yamaguchi, Tatsuro
    Tsuji, Akihito
    Sunakawa, Yu
    Nakamura, Masato
    Kochi, Mitsugu
    Denda, Tadamichi
    Shimada, Ken
    Tani, Satoshi
    Takagane, Akinori
    Kotaka, Masahito
    Kuramochi, Hidekazu
    Koike, Junichi
    Furushima, Kaoru
    Yonemura, Yutaka
    Negoro, Yuji
    Takinishi, Yasutaka
    Takeuchi, Masahiro
    Ichikawa, Wataru
    Fujii, Masashi
    Nakajima, Toshifusa
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [29] Survival benefit of cetuximab in metastatic colorectal cancer
    不详
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2011, 72 (05) : 249 - 249
  • [30] EFFICACY AND SAFETY OF CAPECITABINE AND IRINOTECAN (CAPIRI) IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Bounedjar, Adda
    Smaili, Farida
    ANNALS OF ONCOLOGY, 2011, 22 : v99 - v99
12345